文章预览
SCI 25 November 2024 Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression ≥25%: Results from the Randomized Phase 3 PEARL Study (JTO, IF: 21.0) Lu S, Wu L, Wang Q, et al: Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression ≥25%: Results from the Randomized Phase 3 PEARL Study. J Thorac Oncol S1556-0864(24)02433-X, 2024 Introduction 引言 PEARL (NCT03003962) is an open-label, phase 3 study comparing first-line durvalumab monotherapy with chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC [EGFR/ALK wild type]) with PD-L1 tumor cell (TC) membrane expression status ≥25%. We report the final analysis of PEARL. PEARL (NCT03003962)是一项开放标签的3期临床研究，比较转移性非小细胞肺癌(mNSCLC [ EGFR/ALK 野生型])患者的一线 durvalumab 单药治疗和化疗与 PD-L1肿瘤细胞(TC)膜表达状态≥25% 。我们报告了 PEARL 的
………………………………
